The PubChem BioAssay being referred to in this prompt is a counterscreen designed to identify exosite inhibitors of ADAM17 through the use of a FRET-based biochemical high throughput dose response assay. Its primary goal is to identify inhibitors of ADAM10, with the class of assay being confirmatory and the assay type description being binding. The properties of the assay include its categorization as confirmatory and its designation as a binding assay. When subjected to the assay, does the molecule exhibit sufficient efficacy to achieve the desired result?